Comparative study on the bioequivalence of two formulations of pravastatin: Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 56, Issue 2, 2006, Pages 70-75

  Almeida, Susana ^a,b   Filipe, Augusto ^a   Almeida, Ana ^a   Gich, Ignasi ^c   Antonijoan, Rosa ^c   Puntes, Montserrat ^c   Barbanoj, Manuel ^c   Cruz Caturla, Maria ^d  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Anapharm Europe   (Spain)

Author keywords

CAS 81131 70 6; Lipid reducers; Pravastatin, bioavailability, bioequivalence, gender, pharmacokinetics

Indexed keywords

PRAVASTATIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; GENDER; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY;

EID: 33645097105     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296704     Document Type: Article

References (8)

1. Singhvi, S. M., Pan, H. Y., Morrison, R. A. et al., Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29, 239 (1990)
2. Haria, M., McTavish, D., Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 53, 299 (1997)
3. Lennernas, H., Fager, G., Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403 (1997)
4. 450 inhibitors. Am. J. Cardiol. 94, 1140 (2004)
5. Corsini, A., Belloste, S., Baetta, E. et al., New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413 (1999)
6. CPMP/EWP/QWP/1401/98, Note for Guidance on the Investigation of Bioavailability and Bioequivalence. EMEA, London (2001)
7. Chen, M. L., Lee, S. C., Ng, M. J. et al., Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 68, 510 (2000)
8. Pan, H. Y., Waclawski, A. P., Funke, P. T. et al., Pharmacokinetics of pravastatin in elderly versus young men and women. Ann. Pharmacother. 27, 1029 (1993)